MediWound Ltd.(MDWD)Earnings, Financials & Key Ratios
MDWD•NASDAQ
$14.82
Price updated Jul 2, 2026
AboutMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Show more
- Revenue$17M-16.1%
- EBITDA-$23M-30.8%
- Net Income-$24M+21.0%
- EPS (Diluted)-2.10+30.7%
- Gross Margin19.19%+47.3%
- EBITDA Margin-138.09%-56.0%
- Operating Margin-149.06%-55.5%
- Net Margin-140.8%+5.8%
- ROE-63.86%+33.7%
MDWD Price & Volume
MediWound Ltd. (MDWD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Liquidity Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- MediWound faces a precarious financial outlook characterized by a 62.7% year-over-year revenue decline in 2026Q1 and a structural inability to achieve operational profitability.
- The company's reliance on capital-intensive biological manufacturing, evidenced by $27.3 million in net property, plant, and equipment, continues to outpace commercial revenue generation.
- Investors should remain cautious as the firm's cash reserves and equity base face ongoing erosion, necessitating potential future dilution to sustain clinical development.
Verdict Logic
the company's inability to generate positive operating cash flow, combined with a 2026Q1 operating loss of $8.0 million, suggests significant liquidity risk for shareholders.
MDWD Growth Metrics
MediWound Ltd. (MDWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.65%
5 Years-4.87%
3 Years-13.82%
TTM-24.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8.28%
Return on Capital
10 Years-34.25%
5 Years-44.21%
3 Years-39.31%
Last Year-47.03%
MDWD Recent Earnings
MediWound Ltd. (MDWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 27, 2026Metric
Actual
Est
EPS
$0.23+64.6%
$0.65
Rev
$1M-56.2%
$3M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.56+13.8%
$0.65
Rev
$2M-55.5%
$4M
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.24+70.4%
$0.81
Rev
$5M+160.1%
$2M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.23-123.6%
$0.55
Rev
$6M-13.0%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 27, 2026 | $0.23vs $0.65+64.6% | $1Mvs $3M-56.2% |
| Q2 2026 | Mar 5, 2026 | $0.56vs $0.65+13.8% | $2Mvs $4M-55.5% |
| Q4 2025 | Nov 20, 2025 | $0.24vs $0.81+70.4% | $5Mvs $2M+160.1% |
| Q3 2025 | Aug 14, 2025 | $1.23vs $0.55-123.6% | $6Mvs $7M-13.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for MediWound Ltd. (MDWD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.82 | $160.98M | -7.06 | -16.14% | -140.8% | -63.86% | — | |
| $2.59 | $835.05K | -0.03 | — | — | -516.87% | — | |
| $15.78 | $1.8B | -12.93 | 8.28% | -25.66% | -50.82% | — | |
| $28.49 | $1.39B | -113.96 | 16.97% | -10.52% | -2.91% | — | |
| $10.88 | $348.14M | 4.73 | 6774.96% | -256.6% | -17.04% | — | |
| $77.01 | $9.13B | 30.08 | 37.55% | 23.13% | 126.27% | — |
Compare MDWD vs Peers
MediWound Ltd. (MDWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MDWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDWD Frequently Asked Questions
MediWound Ltd. (MDWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is MediWound Ltd.'s revenue?
MediWound Ltd. (MDWD) reported $14.5M in revenue for fiscal year 2025.
How fast is MediWound Ltd. growing?
MediWound Ltd. (MDWD) saw revenue decline by 16.1% over the past year.
Is MDWD profitable?
MediWound Ltd. (MDWD) reported a net loss of $26.1M for fiscal year 2025.
Dividend & Returns
What is MDWD's return on equity?
MediWound Ltd. (MDWD) has a return on equity (ROE) of -63.9%. Negative ROE indicates the company is unprofitable.
What is MediWound Ltd.'s free cash flow?
MediWound Ltd. (MDWD) had negative free cash flow of $24.3M in fiscal year 2025, likely due to heavy capital investments.